Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ALIVE Israel HealthTech Fund is a venture capital firm established in 2020 and based in Savyon, Israel. The fund focuses on mid-to-late stage investments in the HealthTech sector, aiming to enhance value creation throughout the investment journey. This includes support during clinical trials, FDA approvals, market validation, and product adoption. ALIVE collaborates with a strategic ecosystem of partners, including leading hospital chains, health maintenance organizations (HMOs), and financial institutions, to accelerate the growth of promising technologies.
Currently, ALIVE manages approximately $200 million in assets under management (AUM) across its funds. The firm operates three funds: ALIVE One, which focuses on mid-to-late clinical stage and early commercial stage companies; ALIVE Next, an opportunity fund that follows on promising investments; and ALIVE Growth, which targets growth-stage investments. The firm has a portfolio of 12 companies, demonstrating its commitment to supporting innovative HealthTech solutions.
ALIVE Israel HealthTech Fund invests in mid-to-late stage companies that are developing innovative platform technologies across various sectors, including healthcare, biotech, digital health, and artificial intelligence. The fund specifically targets medical devices, diagnostics, healthcare IT, and digital health solutions. ALIVE seeks companies with strong management teams, robust intellectual property, and a proven execution track record. These companies should be positioned to leverage the strategic synergies offered by ALIVE's extensive ecosystem.
The fund's investment strategy emphasizes collaboration with partners in the healthcare sector, which enhances the growth potential of its portfolio companies. ALIVE's geographic focus is global, with particular interest in the Asian market. The firm typically invests in Series A, Series B, Series C, and growth equity stages, providing check sizes that align with the needs of mid-to-late stage companies.
ALIVE Israel HealthTech Fund's portfolio includes a diverse range of innovative companies:
Prof. Rafael Beyar: Co-Founder and Managing General Partner. Beyar is a renowned interventional cardiologist and biomedical engineer, previously serving as the Director of Rambam Health Care Campus.
Michel Habib: Co-Founder and Managing General Partner. Habib has extensive experience in healthcare innovation and investment.
Prof. Ari Shamiss: Co-Founder and Managing General Partner. Shamiss brings a wealth of knowledge in clinical operations and healthcare management.
Dudi Klein: Co-Founder and Managing Partner. Klein previously headed the innovation division at Assuta Medical Centers, focusing on advancing healthcare technologies.
ALIVE's team also includes investment associates Alison Sebbag and Noy Hoffman, who contribute to the firm's investment strategy and portfolio management.
To pitch to ALIVE Israel HealthTech Fund, founders should use the contact email provided: shir@alivevc.com. A well-structured pitch deck is essential, including information about the company's technology, market opportunity, and team. ALIVE prefers pitches that demonstrate a clear understanding of the regulatory landscape and market needs.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions can enhance the chances of a successful pitch, so leveraging connections within the HealthTech community is advisable.
In recent months, ALIVE Israel HealthTech Fund has continued to expand its portfolio, focusing on mid-to-late stage investments in HealthTech. The fund has been actively involved in optimizing value creation across the investment journey, particularly in clinical trials and market validation.
ALIVE's notable exits include the acquisition of Innovalve by Edwards Lifesciences and Cynerio by Axonius, showcasing the fund's ability to identify and support successful HealthTech companies. The firm is also preparing for the initial close of its third fund, ALIVE Growth, which aims to raise approximately $200 million for growth-stage investments.
What are ALIVE's investment criteria?
ALIVE focuses on mid-to-late stage companies in the HealthTech sector, specifically those developing innovative platform technologies in medical devices, diagnostics, digital health, healthcare IT, and AI. The fund seeks companies with strong management teams, robust intellectual property, and a proven execution track record.
How can I pitch to ALIVE?
Founders can pitch to ALIVE by visiting their website at www.alivevc.com and using the contact email provided. A well-prepared pitch deck should include details about the company's technology, market potential, and team.
What makes ALIVE different from other investors?
ALIVE distinguishes itself through its strategic partnerships with leading hospital chains and HMOs, providing portfolio companies with access to a robust clinical network and regulatory expertise. This enhances the growth potential and market adoption of their investments.
What is the geographic scope of ALIVE's investments?
ALIVE has a global investment focus, with particular interest in the Asian market. The firm aims to support HealthTech companies that are ready to scale and commercialize their solutions internationally.
What is the typical check size for investments?
ALIVE invests in Series A, Series B, Series C, and growth equity stages, with check sizes that align with the needs of mid-to-late stage companies. Specific amounts may vary based on the company's stage and requirements.
What kind of support does ALIVE provide post-investment?
ALIVE offers significant value to its portfolio companies through access to a clinical network, regulatory expertise, and commercial introductions via partnerships with HMOs and hospitals. This support facilitates faster market adoption and scaling of their technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.